Tysabri Sales Dip But Don’t Swoon After PML Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.